原发性胆汁性胆管炎是一种慢性自身免疫性胆汁淤积性疾病,主要发生在中老年女性,PBC的发病率和患病率在不同地区和时期差异性较大。原发性胆汁性胆管炎的发病机制尚不明确,现普遍认为PBC的发病涉及遗传因素、环境因素和免疫因素。目前,除了熊去氧胆酸(UDCA)、奥贝胆酸以及贝特类药物被批准用于PBC患者的治疗,更多的新型药物以及治疗方法正处于临床研发的不同阶段。Primary biliary cholangitis is a chronic autoimmune cholestasis disease, mainly occurring in middle-aged and elderly women. The incidence and prevalence of PBC vary greatly in different regions and periods. The pathogenesis of primary biliary cholangitis is still unclear, but it is generally believed that the pathogenesis of PBC involves genetic factors, environmental factors and immune factors. At present, in addition to Ursodeoxycholic Acid (UDCA), obecholic acid and bate drugs are approved for the treatment of PBC patients, more new drugs and treatments are in different stages of clinical research and development.
暂无评论